|1.||Yano, S: 1 article (10/2000)|
|2.||Beers, R: 1 article (10/2000)|
|3.||Shinohara, H: 1 article (10/2000)|
|4.||Pastan, I: 1 article (10/2000)|
|5.||Fan, D: 1 article (10/2000)|
|6.||Ozawa, S: 1 article (10/2000)|
|7.||Van Arsdell, M: 1 article (10/2000)|
|8.||Viner, J L: 1 article (10/2000)|
|9.||Fidler, I J: 1 article (10/2000)|
|1.||Neoplasm Metastasis (Metastasis)
10/06/1995 - "B3(Fv)-PE38 is specifically cytotoxic to many human cancer cell lines and is currently evaluated in a clinical trial. "
06/01/1997 - "The immunotoxins LMB-1 and LMB-7 contain PE38 and kill cancer cells by exploiting the cytotoxic action of PE38. "
12/01/1998 - "Despite inhibition of apoptosis, the immunotoxin is still capable of selective cell killing, which indicates that B3(Fv)-PE38 kills cells by two mechanisms: one requires caspase activation, and the other is due to the arrest of protein synthesis caused by inactivation of elongation factor 2. The fact that an immunotoxin can specifically kill tumor cells without the need of inducing apoptosis makes such agents especially valuable for the treatment of cancers that are protected against apoptosis, e.g., by overexpression of Bcl-2."
10/06/1995 - "The B3(Fv)-PE38 immunotoxin binds to antigen-positive cancer cells with a higher affinity than B5(Fv)-PE38 and is a more potent cytotoxic agent than B5(Fv)-PE38. "
03/28/1995 - "Lack of significant toxicity in the effective dose range and specificity make LMB-7 an excellent candidate for intrathecal treatment of neoplastic meningitis in humans."
03/28/1995 - "We tested the therapeutic value of intrathecally administered LMB-7 by using a model of human neoplastic meningitis in athymic rats. "
|2.||Peptide Elongation Factor 2 (EF-2)